1 Min Read
June 28 (Reuters) - Global Blood Therapeutics Inc
* Global blood therapeutics receives ema prime designation for gbt440 for the treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.